Geode Capital Management LLC Takes Position in CeriBell (NASDAQ:CBLL)

Geode Capital Management LLC bought a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 257,070 shares of the company's stock, valued at approximately $6,654,000. Geode Capital Management LLC owned 0.72% of CeriBell at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CBLL. PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell during the fourth quarter valued at approximately $47,000. Corebridge Financial Inc. acquired a new stake in CeriBell during the 4th quarter valued at $158,000. Rhumbline Advisers acquired a new stake in shares of CeriBell in the fourth quarter worth $320,000. Norges Bank purchased a new position in shares of CeriBell during the fourth quarter valued at $422,000. Finally, Alliancebernstein L.P. acquired a new position in CeriBell during the fourth quarter valued at $532,000.

CeriBell Stock Down 0.6 %

NASDAQ:CBLL traded down $0.09 during mid-day trading on Thursday, reaching $16.00. 25,315 shares of the company were exchanged, compared to its average volume of 269,947. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75. The firm's fifty day moving average is $19.22.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. As a group, equities analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

CBLL has been the subject of a number of research analyst reports. LADENBURG THALM/SH SH initiated coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $32.50.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 3,372 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $15.03, for a total transaction of $50,681.16. Following the completion of the transaction, the chief executive officer now directly owns 743,079 shares of the company's stock, valued at $11,168,477.37. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 24,700 shares of company stock valued at $372,434 over the last quarter.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.